This paper introduces human myelin spheres (MyS) as a model for studying myelination and demyelination, showing their ability to form myelinated neurons and mimic in vivo oligodendrocyte development.

Stem Cell Reviews and Reports · Jan 28, 2026Peer-reviewedNeuroscience

Discovery of orally bioavailable Zika virus NS2B-NS3 protease inhibitors with efficacy in a murine infection model

Nathaniel T. Kenton, Haim Michael Barr, Artem Cherepakha, Lotte Coelmont, Caroline Collard, David Cousins, Geraint H. M. Davies, Oleksii Degtyarenko, Andrew Dirksen, Daniel Elbrecht, D. Fearon, James R. Gayvert, Ed Griffen, Dirk Jochmans, Suzanne J. F. Kaptein, , Alpha A. Lee

The paper identifies orally bioavailable inhibitors of the Zika virus NS2B-NS3 protease that show antiviral activity in vitro and reduce viral RNA load in a murine infection model.

bioRxiv · Jun 19, 2025 · PreprintMicrobiology

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor

Ed Griffen, D. Fearon, Briana Lynn McGovern, L. Koekemoer, Blake H. Balcomb, Tamás Szommer, Gwendolyn Fate, Ralph P. Robinson, Bruce A. Lefker, Shirly Duberstein, Noa Lahav, Stéphanie Braillard, Laura Vangeel, Manon Laporte, Fabienne Burgat Charvillon, , Annette von Delft

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

bioRxiv · Jun 16, 2025 · PreprintPharmacology & Toxicology

The combination of GS-441524 (remdesivir) and ribavirin results in a potent antiviral effect against human parainfluenza virus 3 infection in human airway epithelial cell cultures and in a mouse infection model

Yuxia Lin, Birgit Weynand, Xin Zhang, Manon Laporte, Dirk Jochmans, Johan H. Neyts

This study shows that combining remdesivir and ribavirin significantly reduces HPIV-3 infection in cell cultures and mice, with minimal lung pathology.

Viruses · Jan 26, 2025Peer-reviewedMicrobiology

The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model

Thuc Nguyen Dan, Rana Abdelnabi, Bernadett Boda, Samuel Constant, Johan H. Neyts, Dirk Jochmans

This paper evaluates a triple antiviral combination's efficacy against coronavirus in cell cultures and a hamster model, finding enhanced antiviral effects even with suboptimal doses.

Antiviral Research · Sep 3, 2024Peer-reviewedMicrobiology

Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen

Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geißlinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, , Andrea Zaliani

The paper identifies 62 new inhibitors of SARS-CoV-2 3CL-Pro through a compound repurposing screen and validates their activity using X-ray crystallography.

ACS Pharmacology & Translational Science · Mar 11, 2021Peer-reviewedMolecular Biology

Drug development of an affinity enhanced, broadly neutralizing heavy chain-only antibody that restricts SARS-CoV-2 in rodents

Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijałkowska, Simon Devos, Wannes Weyts, Sieglinde De Cae, Sandrine Vanmarcke, Chiara Lonigro, Hannah Eeckhaut, Dries Van Herpe, Jimmy Borloo, ANDREZA ESTEFANY DA SILVA OLIVEIRA, , Xavier Saelens

The paper describes the development of a broadly neutralizing antibody, XVR011, effective against SARS-CoV-2 and its variants in animal models.

bioRxiv · Mar 8, 2021 · PreprintMolecular Biology